RECEIVED
CENTRAL FAX CENTER
NOV 2 2 2006

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of treating or inhibiting a disease that is caused or enhanced by induction of a cytokine-2 receptor, in a patient in need thereof, the cytokine-2 being a member of the IL-1 family, the method comprising administration of an effective amount of a cytokine-1 to bind to the cytokine-2 receptor, wherein the cytokine-1 is IL-1F7b and wherein the IL-1F7b is administered together with IL-18BP or mutein, fused protein, functional derivative or fragment thereof.

2-4. (Cancelled)

5. (Original) The method of claim 1, wherein the cytokine-2 receptor is IL-18R.

6. (Original) The method of claim 1, wherein the cytokine-1 binds to the signalling chain of the cytokine-2 receptor.

7. (Original) The method of claim 1, wherein the disease is an inflammatory disease.

8-9. (Cancelled)

10. (Original) The method of claim 1, wherein the cytokine-1 is administered systemically, subcutaneously or intramuscularly.

11-40. (Cancelled)

41. (New) A method of treating an inflammatory disease that is caused or enhanced by induction of a cytokine-2 receptor, in a patient in need thereof, the cytokine-2 being IL-18, the method comprising administration of an effective amount of a cytokine-1 to bind to the cytokine-2 receptor, wherein the cytokine-1 is IL-1F7b and wherein the IL-1F7b is administered together with IL-18BP.

42. (New) The method of claim 41, wherein the disease is arthritis, ulcerative colitis, or Crohn's disease.

PAGE 9/19 * RCVD AT 11/22/2006 12:45:18 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-2/21 * DNIS:2738300 * CSID:18667410075 * DURATION (mm-ss):08-00